Ex vivo generation of highly purified and activated natural killer cells from human peripheral blood

Human Gene Therapy Methods

Volumn 24, Issue 4, 2013, Pages 241-252

  Saito, Satoru ^a,b   Harada, Yui ^b   Morodomi, Yosuke ^b,c   Onimaru, Mitsuho ^c   Yoshida, Kumi ^b   Kyuragi, Ryoichi ^c   Matsubara, Hisahiro ^a   Yonemitsu, Yoshikazu ^b  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD56 ANTIGEN; CD69 ANTIGEN; GAMMA INTERFERON; GRANZYME B; INTERLEUKIN 2; LYMPHOCYTE SURFACE MARKER; NATURAL KILLER CELL RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2D; PERFORIN;

ACTIVATED NATURAL KILLER CELL; ANALYTICAL PARAMETERS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL EXPANSION; CELL ISOLATION; CELL KILLING; CELL STRAIN K 562; CELL VIABILITY; CONTROLLED STUDY; CRYOPRESERVATION; CULTURE MEDIUM; EMBRYO; EVALUATION; EX VIVO STUDY; FEMALE; FETUS; HUMAN; HUMAN CELL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; MAJOR HISTOCOMPATIBILITY COMPLEX; MAJOR HISTOCOMPATIBILITY COMPLEX 1; MOUSE; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PURIFIED NATURAL KILLER CELL; TUMOR CELL DESTRUCTION; ZENITHAL NATURAL KILLER CELL;

ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; FEMALE; FLOW CYTOMETRY; HUMANS; INTERFERON-GAMMA; K562 CELLS; KILLER CELLS, LYMPHOKINE-ACTIVATED; LECTINS, C-TYPE; MICE; MICE, INBRED NOD; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84882991676     PISSN: 19466536     EISSN: 19466544     Source Type: Journal    
DOI: 10.1089/hgtb.2012.183     Document Type: Article

References (36)

1. Aparicio-Pagés, M.N., Verspaget, H.W., Peñ a, A.S., and Lamers, C.B. (1991). Natural killer cell activity in patients with adenocarcinoma in the upper gastrointestinal tract. J. Clin. Lab. Immunol. 35, 27-32.
2. Arai, S., Meagher, R., Swearingen, M., et al. (2008). Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. Cytotherapy 10, 625-632.
3. Berg, M., and Childs, R. (2010). Ex-vivo expansion of NK cells: What is the priority-high yield or high purity? Cytotherapy 12, 969-970.
4. Berg, M., Lundqvist, A., McCoy, P. Jr., et al. (2009). Clinicalgrade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy 11, 341-355.
5. Biassoni, R., Cantoni, C., Marras, D., et al. (2003). Human natural killer cell receptors: insights into their molecular function and structure. J. Cell. Mol. Med. 7, 376-387. (Pubitemid 44151688)
6. Brittenden, J., Heys, S.D., Ross, J., and Eremin, O. (1996). Natural killer cells and cancer. Cancer 77, 1226-1243. (Pubitemid 26102319)
7. Caligiuri, M.A. (2008). Human natural killer cells. Blood 112, 461-469.
8. Carlens, S., Liu, D., Ringden, O., et al. (2002). Cytolytic T cell reactivity to Epstein-Barr virus is lost during in vitro T cell expansion. J. Hematother. Stem. Cell. Res. 11, 669-674. (Pubitemid 34851798)
9. Castriconi, R., Dondero, A., Cilli, M., et al. (2007). Human NK cell infusions prolong survival of metastatic human neuroblastoma-bearing NOD/scid mice. Cancer. Immunol. Immunother. 56, 1733-1742. (Pubitemid 47313078)
10. Chuang, W.L., Liu, H.W., and Chang, W.Y. (1990). Natural killer cell activity in patients with hepatocellular carcinoma relative to early development and tumor invasion. Cancer 65, 926-930.
11. Freud, A.G., and Caligiuri, M.A. (2006). Human natural killer cell development. Immunol. Rev. 214, 56-72. (Pubitemid 44707902)
12. Gattinoni, L., Klebanoff, C.A., Palmer, D.C., et al. (2005). Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8 + T cells. J. Clin. Invest. 115, 1616-1626. (Pubitemid 40814670)
13. Geller, M.A., Cooley, S., Judson, P.L., et al. (2011). A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy 13, 98-107.
14. Gonzalez, F.M., Vargas, J.A., Lopez-Cortijo, C., et al. (1998). Prognostic significance of natural killer cell activity in patients with laryngeal carcinoma. Arch. Otolaryngol. Head Neck. Surg. 124, 852-856. (Pubitemid 28369201)
15. Grimm, E.A., Mazumder, A., Zhang, H.Z., and Rosenberg, S.A. (1982). Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J. Exp. Med. 155, 1823-1841. (Pubitemid 12074218)
16. Karre, K. (2002). NK cells, MHC class I molecules and the missing self. Scand. J. Immunol. 55, 221-228. (Pubitemid 34310025)
17. Kishi, A., Takamori, Y., Ogawa, K., et al. (2002). Differential expression of granulysin and perforin by NK cells in cancer patients and correlation of impaired granulysin expression with progression of cancer. Cancer. Immunol. Immunother. 50, 604-614.
18. Koehl, U., Sö rensen, J., Esser, R., et al. (2004). IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation. Blood. Cells. Mol. Dis. 33, 261-266. (Pubitemid 39446496)
19. Koehl, U., Esser, R., Zimmermann, S., et al. (2005). Ex vivo expansion of highly purified NK cells for immunotherapy after haploidentical stem cell transplantation in children. Klin Padiatr. 217, 345-350. (Pubitemid 41746117)
20. Komaru, A., Ueda, Y., Furuya, A., et al. (2009). Sustained and NK/CD4+ T cell-dependent efficient prevention of lung metastasis induced by dendritic cells harboring recombinant Sendai virus. J. Immunol. 183, 4211-4219.
21. Kondo, E., Koda, K., Takiguchi, N., et al. (2003). Preoperative natural killer cell activity as a prognostic factor for distant metastasis following surgery for colon cancer. Dig. Surg. 20, 445-451. (Pubitemid 37116950)
22. Lahat, N., Alexander, B., Levin, D.R., and Moskovitz, B. (1989). The relationship between clinical stage, natural killer activity and related immunological parameters in adenocarcinoma of the prostate. Cancer. Immunol. Immunother. 28, 208-212. (Pubitemid 19062292)
23. Law, T.M., Motzer, R.J., Mazumdar, M., et al. (1995). Phase III randomized trial of interleukin-2 with or without lymphokineactivated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer 76, 824-832.
24. Leung, W., Iyengar, R., Leimig, T., et al. (2005). Phenotype and function of human natural killer cells purified by using a clinical-scale immunomagnetic method. Cancer. Immunol. Immunother. 54, 389-394. (Pubitemid 40238933)
25. Ljunggren, H.G., and Karre, K. (1990). In search of the missing self: MHC molecules and NK cell recognition. Immunol. Today. 11, 237-244. (Pubitemid 20198988)
26. Matter, M., Pavelic, V., Pinschewer, D.D., et al. (2007). Decreased tumor surveillance after adoptive T-cell therapy. Cancer. Res. 67, 7467-7476. (Pubitemid 47206576)
27. Natarajan, K., Dimasi, N., Wang, J., et al. (2002). Structure and function of natural killer cell receptors: multiple molecular solutions to self, nonself discrimination. Annu. Rev. Immunol. 20, 853-885. (Pubitemid 34293442)
28. Rosenberg, S. (1985). Lymphokine-activated killer cells: a new approach to immunotherapy of cancer. J. Natl. Cancer. Inst. 75, 595-603. (Pubitemid 16222388)
29. Rosenberg, S.A., Lotze, M.T., Yang, J.C., et al. (1993). Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J. Natl. Cancer. Inst. 85, 622-632. (Pubitemid 23120507)
30. Rubnitz, J.E., Inaba, H., Ribeiro, R.C., et al. (2010). NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J. Clin. Oncol. 28, 955-959.
31. Ruggeri, L., Capanni, M., and Urbani, E. (2002). Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295, 2097-2100. (Pubitemid 34229476)
32. Speiser, D.E., and Romero, P. (2005). Toward improved immunocompetence of adoptively transferred CD8 + T cells. J. Clin. Invest. 115, 1467-1469. (Pubitemid 40814653)
33. Suck, G., and Koh, M.B. (2010). Emerging natural killer cell immunotherapies: large-scale ex vivo production of highly potent anticancer effectors. Hematol. Oncol. Stem. Cell. Ther. 3, 135-142.
34. Suck, G., Oei, V.Y., Linn, Y.C., et al. (2011). Interleukin-15 supports generation of highly potent clinical-grade natural killer cells in long-term cultures for targeting hematological malignancies. Exp. Hematol. 39, 904-914.
35. Sutlu, T., and Alici, E. (2009). Natural killer cell-based immunotherapy in cancer: current insights and future prospects. J. Intern. Med. 266, 154-181.
36. Sutlu, T., Stellan, B., Gilljam, M., et al. (2010). Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor. Cytotherapy 12, 1044-1055.